Last reviewed · How we verify
Comparator: fluticasone
Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune cell activation and inflammatory mediator release.
Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune cell activation and inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Comparator: fluticasone |
|---|---|
| Also known as | fluticasone |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that works by binding to intracellular glucocorticoid receptors in airway tissues, leading to decreased production of inflammatory cytokines, reduced recruitment of eosinophils and other immune cells, and decreased mucus production. This results in reduced airway inflammation, bronchial hyperresponsiveness, and airway remodeling in respiratory conditions.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Tremor
- Headache
- Dysphonia
- Palpitations
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) (PHASE3)
- Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil (PHASE3)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- First Step With Singulair® Therapy (0476-323) (PHASE4)
- A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: fluticasone CI brief — competitive landscape report
- Comparator: fluticasone updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI